AusperBio Alternatives & Competitors
12 companies similar to AusperBio — Transforming Patient Lives For a Better Tomorrow
Companies similar to AusperBio
Atea Pharmaceuticals, Inc
Discovery & development of breakthrough therapies for COVID-19 patients and severe viral d...
Boston, United States
Antios Therapeutics
Antios Therapeutics is a clinical-stage biopharmaceutical company devoted to developing th...
Atlanta, United States
RIGImmune Inc.
Targeted non-LNP Delivery of RNA Therapeutics
Farmington, United States
OrsoBio
Advancing first-in-class therapies to restore energy homeostasis
Palo Alto, United States
Rival Readout
Competing with AusperBio? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
-logo.jpg "Entero Therapeutics (Nasdaq: ENTO)"){kind=logo}
Entero Therapeutics (Nasdaq: ENTO)
A biopharma company focused on the development of targeted, non-systemic therapies for gas...
Boca Raton, United States
Skye Bioscience Inc.
Unlocking new therapeutic pathways for metabolic health
San Diego, United States
Rampart Bioscience
Leading a new era of effective, safe and accessible gene medicines.
Monrovia, United States
Autotelic Bio Inc.
RNA Therapeutics New Drug Development Company
Korea South
Soleno Therapeutics, Inc.
Inspired by patients and families around the world, we are advancing much needed therapies...
Redwood City, United Stat...
Calithera Biosciences
Targeting cancer, differently.
South San Francisco, Unit...
Aera Therapeutics
Enabling the next generation of transformative genetic medicines
Cambridge, United States
About AusperBio
AusperBio, founded in 2019, is a clinical-stage biopharmaceutical company with dual operations in the USA and China. Guided by its ambitious slogan, "Transforming Patient Lives For a Better Tomorrow," the company focuses on advancing oligonucleotide and targeted delivery technologies to offer transformative therapies,...
development of oligonucleotide therapeutics, HBV cure solutions, disease transformation therapies
healthcare providers, patients with HBV, patients with viral, metabolic, genetic, and immune conditions, biopharmaceutical researchers
Clinical-stage Biopharmaceuticals, Oligonucleotide Therapeutics, Targeted Delivery Technologies, Med-Oligo ASO Platform, Chronic Hepatitis B Treatment, Transformative Therapies, Genetic Disorders, Viral Infections, Metabolic Conditions, Immune Diseases, Phase II Clinical Trials, Proprietary Technology, Conjugation Technologies, Therapeutic Development, Biopharmaceutical Innovation
B2B, B2D
Licensing, Product Sales
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around AusperBio: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at AusperBio on 11 Mar 2026. The 12 companies listed here were last checked between 12 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
